BioAtla, Inc. BCAB
Nov 4, 2026, 1:45 PM EST
- YTD
- -92.96%
- 1 year
- -93.98%
- Market cap
- 3.34M
- Revenue (ttm)
- 11.00M
- EPS (ttm)
- -25.23
- Shares out
- 48.35M
- Forward P/E
- -0.42
- YTD return
- -92.96%
- 1-year return
- -93.98%
- Volume
- 1.24K
- Avg volume
- 52.69K
- Open
- 1.87
- Previous close
- 1.87
- Day's range
- 1.87 – 2.00
- 52-week range
- 1.07 – 71.50
- Beta
- 1.02
- Price target
- 9.00 (+350.0%)
- Earnings date
- Aug 8, 2024
1Y -31.70 (-94.07%)
Key statistics
- Enterprise value
- -21.80M
- PEG ratio
- 0.00
- Price / sales
- 2.73
- Price / book
- 1.31
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -56.73M
- Total cash
- 56.52M
- Total debt
- 1.25M
- Return on equity
- -139.06%
- Short % of float
- 9.21%
- 50-day average
- 1.72
- 200-day average
- 1.99
Analyst view
- Target (low)
- 5.00
- Target (mean)
- 9.00
- Target (high)
- 13.00
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.34.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.34 | -0.22 | +0.12 | +35.29% |
| Aug 8, 2024 | Jun 1, 2024 | -0.45 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.45 | -0.44 | +0.01 | +2.22% |
| May 14, 2024 | Mar 1, 2024 | -0.57 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.57 | -0.48 | +0.09 | +15.79% |
| Mar 26, 2024 | Dec 1, 2023 | -0.68 | -0.56 | +0.12 | +17.65% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Sep 16, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| May 23, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 28, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Mar 27, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bioatla.com
News
12 Health Care Stocks Moving In Friday's Intraday Session 
12 Health Care Stocks Moving In Friday's Pre-Market Session - 12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on BCAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GRAY MARY ANN | Director | Stock Award(Grant) | Jun 12, 2024 | 53,897 |
| MCBRINN SYLVIA | Director | Stock Award(Grant) | Jun 12, 2024 | 35,625 |
| MORAN SUSAN M | Director | Stock Award(Grant) | Jun 12, 2024 | 28,807 |
| SHORT JAY M | Chief Executive Officer | Stock Award(Grant) | Feb 15, 2024 | 3,469,660 |
| SIEVERS ERIC L | Officer | Stock Award(Grant) | Feb 14, 2024 | 211,566 |
| SMITH SCOTT ANDREW | Director | Stock Award(Grant) | Jun 12, 2024 | 304,593 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Millennium Management Llc | 5.50% | 2,659,589 | 1.65M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 5.21% | 2,517,478 | 1.56M | Sep 29, 2024 |
| Vanguard Group Inc | 3.90% | 1,885,252 | 1.17M | Sep 29, 2024 |
| Morgan Stanley | 3.84% | 1,858,176 | 1.15M | Sep 29, 2024 |
| Tang Capital Management, LLC | 1.81% | 874,076 | 542.45K | Sep 29, 2024 |
| Boxer Capital, LLC | 1.42% | 686,347 | 425.95K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.63% | 1,269,840 | 788.06K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.14% | 549,449 | 340.99K | Sep 29, 2024 |
| MFS New Discovery Fund | 0.70% | 339,507 | 210.70K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.47% | 228,913 | 142.06K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.24% | 115,000 | 71.37K | Sep 29, 2024 |
| MFS Variable Insurance Trust-MFS New Discovery Series | 0.22% | 108,773 | 67.50K | Sep 29, 2024 |